International Journal of Pathogen Research

Volume 13, Issue 5, Page 61-69, 2024; Article no.IJPR.123334
ISSN: 2582-3876

Antimicrobial Resistance in Uropathogens Associated with Community Acquired Urinary Tracts Infections in Port Harcourt, Nigeria

Chidi L.C. Ndukwu [a*] and Ijeoma F. Ndu [a]

[a] *Faculty of Medical Laboratory Science, Federal University Otuoke, Bayelsa State, Nigeria.*

Authors' contributions

This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

Article Information

DOI: https://doi.org/10.9734/ijpr/2024/v13i5310

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/123334

Original Research Article

Received: 14/07/2024
Accepted: 16/09/2024
Published: 24/09/2024

ABSTRACT

Introduction: Antimicrobial resistance (AMR) in uropathogens remain an intractable public health concern due to the associated mortality, morbidity and economic and manpower losses worldwide. This retrospective study was aimed at ascertaining the prevalence of the bacterial uropathogens and the antimicrobial resistance patterns of the dominant strains.
Methodology: It involved a review of laboratory records of the over 1426 males (38%) and females (62%) of various s age brackets between January 1, 2021 and December 31, 2022.
Results: Out of 1426 urine culture samples 58.5% were negative cultures while 592 (41.5%) yielded bacterial growths. A total of 403 uropathogens comprising 11 species were obtained. Gram negative bacteria constitute 73.9% of the isolates while gram positive bacteria were 26.1% *Escherichia coli* (54.7%) was the dominant strains, followed by *Staphylococcus aureus* (10.3%,

---

**Corresponding author: Email: chidisteve.cn@gmail.com;*

***Cite as:** Ndukwu, Chidi L.C., and Ijeoma F. Ndu. 2024. "Antimicrobial Resistance in Uropathogens Associated With Community Acquired Urinary Tracts Infections in Port Harcourt, Nigeria". International Journal of Pathogen Research 13 (5):61-69. https://doi.org/10.9734/ijpr/2024/v13i5310.*

Enterococcus faecalis (9.5%), *Proteus mirabilis* (7.7%, *Staphylococcus saprophyticus* (5.7%, *Streptococcus pneumoniae* (3.9%), *Klebsiella pneumoniae* 17 (3.0%), *Pseudomonas aeruginosa* (2.7%), *Enterobacter cloacae* (1.1%), *Acinetobacter baumannii* (0.9%) and *Serratia marcescens* (0.5%). A cumulative of 50.5% of the strains were resistant to at least on antimicrobial agent. The most resistant uropathogen was *Pseudomonas aeruginosa* with a resistant profile of 64.1%, followed by *Klebsiella pneumoniae* (63.7%), *Staphylococci* (55.7%), *Streptococcus pneumoniae* (55.2%), *Acinetobacter baumannii* (51.7%), *Proteus mirabilis* (51.4%), *Escherichia coli* (48.0%), *Enterobacter cloacae* (47.1%), *Enterococcus faecalis* (46.5%) and *Serratia marcescens* (43.3%) The least effective antimicrobial agent was nitrofurantoin which resisted by 87.1% strains, the most effective was streptomycin (22.2%).

Conclusion: This study will benefit healthcare practitioners in the empirical choice of antibiotics against UTI; however, the high prevalence of AMR necessitates conduct of urine cultures to identify particular uropathogens appropriate antimicrobials in other to curtail increase in AMR among uropathogens.

Keywords: Antimicrobial resistance; uropathogens; Escherichia coli; community acquired urinary tract infections.

1. INTRODUCTION

Urinary tract infections (UTI) constitute a major issue of public health and a foremost cause of morbidity and attendant costs in terms of economic and manpower losses worldwide [1-4]. UTI may be community acquired or nosocomial. The community acquired infection occurs when a person gets infected with any of the etiological agents prior to being admitted in a hospital as contrasted with nosocomial or hospital acquired urinary tract infections which as the name suggests is contracted during stay in the hospital. Community acquired UTI is more prevalent in developing or resource challenged countries [5,6]. UTI may also be classified as uncomplicated and complicated; most community acquired infections are uncomplicated especially in healthy adults including non-pregnant women; while complicated UTI is more prevalent with nosocomial infections especially catheterized and surgical patients or those who are otherwise immuno-compromised [7]. Another classification is based on the site of infection along the urinary tract such as pyelonephritis, cystitis, prostatitis, urethritis etc [2].

Like most infections, UTI may be symptomatic or asymptomatic. Symptoms may include frequent micturition, urgency, dysuria, chills, fever, supra-pubic pain, nausea, vomiting etc [8]. Bacterial uropathogens constitute up to 95% of the etiologic agents of UTI with a vast majority being Gram negative rods; *Escherichia coli* remains the foremost and predominant uropathogen, with between 45 and 95% of the infections attributable to it. Other prevalent pathogens include *Klebsiella*, *Proteus, Pseudomonas, Acinetobacter, Enterobacter*, and *Citrobacter*; the associated Gram-positive bacterial include *Staphylococci* and *Enterococci* [2,7].

The gold standard in the diagnosis of UTI is conventional culture method testing to identify the causative organisms and the most appropriate antimicrobial agents for treatment. However, the high prevalence and the need to commence treatment immediately as well as the absence of adequate laboratory facilities in some areas, often necessitates the commencement of treatment empirically while awaiting culture results where it is available. This makes imperative the possession of information on the resistance/ susceptibility patterns of the etiologic agents of UTI, in order to make appropriate choice of effective [9,10].

Probably more worrisome than the global public health challenge posed by the widespread prevalence of uropathagens is the pervasive and increasing menace of antimicrobial resistance which has been constricting the choice of antibiotics used in the treatment of UTI, given particularly that the acute infections are mostly treated by empirical choice of antibiotics [5]. Inappropriate use, misuse and abuse of antibiotics particularly in resource poor countries where these drugs are available across the counter, coupled with minimal or absence of regulatory controls has continued to conspired with other factors such as absence laboratory facilities and healthcare personnel, scarcity of quality antimicrobial agents, increase in fake and adulterated drugs to complicate the problem of multidrug resistance [5,9].

This study was thus aimed at ascertaining the prevalence of the bacterial uropathogens and determining the antimicrobial resistance patterns of the dominant strains. It sought to provide empirical evidence for personnel involved in prescription and administration of antibiotics to make a better-informed decision in the selection and administration of antimicrobial agents.

2. METHODOLOGY

2.1 Design and Setting

This is a retrospective, cross sectional, observational research carried out between January 1, 2021 and December 31, 2022 at Diagnostix and Scientifique Medical and Research Laboratories in Port Harcourt. It was essentially a review of the laboratory records of the over 1426 patients including males and females of various age groups, referred from public and private healthcare facilities as well as walk-in patients. The clean-catch urine specimens collected in wide-mouthed universal containers were received, recorded and analyzed for microscopy, culture and sensitivity. All those whose records completely captured the details of their names, age, sex, bacteria isolated, resistant and susceptible drugs were included in the study while those with incomplete records were excluded.

2.2 Collection and Analysis of Patients Data

Using a data collection checklist, information about the sex, age, bacterial strains and antibiograms were obtained from the laboratory records.

2.3 Collection of samples, Isolation and Identification of Uropathogens

As stated in the standard operational procedure (SOP) midstream clean catch urine samples were collected in sterile, wide mouthed universal bottles and analyzed within two hours of collection. They were inoculated on sterile culture plates of Cystine–Lactose–Electrolyte-Deficient (CLED) agar, Blood Agar and MacConkey Agar. Standard wire loops of 1 μL in diameter were used in the inoculation, followed by incubation at 37^0c for 24-hour period. The number of colonies were counted to determine the significance of the number of colony-forming units (CFU). The cultures with significant colony counts, i.e. counts up to 10^5 CFU/ml were carefully examined and the relevant colonial characteristics were recorded. Gram staining and relevant biochemical tests were then carried out for the identification of the uropathogens [11].

2.4 Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing (AST) was carried out using the Kirby-Bauer disk-diffusion method. Muller-Hinton agar was prepared by following the manufacturers' guidelines and poured into sterile petri dishes; and were seeded with the relevant susceptibility disks. The antimicrobial agents tested were: Amoxicillin/cloxacillin(20µg), Azithromycin (30 µg), Ceftriaxone (30 µg), Chloramphenicol (30 µg), Ciprofloxacin (10 µg), Levofloxacin(20µg), Gentamicin (10 µg), Norfloxacin (10 µg), Rifampicin (20 µg), Streptomycin (30 µg) (Oxoid, England). Resistance data were interpreted according to National Committee for Clinical laboratory Standards (NCCLS) [12].

2.5 Data Analysis

Descriptive statistical analysis was carried out using the Microsoft Excel spreadsheet software 2017.

3. RESULTS

3.1 Frequencies of Distribution of Samples and Growths of Uropathogens

A total of 834 (58.5%) were negative cultures while 592 (41.5%) yielded bacterial growths; 374 (63.2%) of the positive cultures were females while 218 (36.8%) samples were produced by males. With regards to the age groups, a preponderant of the samples came from the 31 to 40 and 21 to 30 age brackets with 356 (25%) and 328 (23%) of the samples respectively. The proportion of samples collected from the other age brackets were as follows: 41 – 50 (199; 14%), 11 – 20 (186; 13%), 51- 60 (156; 10.9), above 60 (102; 7.2%) and ages 10 years or less (99;6.9%) The highest number of isolates (111; 18.8%) were obtained from the 21 to 30 years age bracket, followed by 110 (18.6%) from the 31 -40 years bracket; the least number of isolates (37; 6.3%) were recovered from the ages of 10 years and Table 1.

Table 1. Frequency of distribution of samples and growths of uropathogens associated with Community acquired UTI

Age (years)	Number of samples						Absence of Pathogens						Presence of Pathogens					
	F	**%**	**M**	**%**	**T**	**%**	**F**	**%**	**M**	**%**	**T**	**%**	**F**	**%**	**M**	**%**	**T**	**%**
≤10	56	6.3	43	7.9	99	6.9	41	8.0	21	5.9	62	7.4	25	6.2	12	7.6	37	6.3
11 -10	134	15.2	52	9.6	186	13.0	71	13.9	31	8.8	102	12.2	58	14.6	26	16.5	84	14.2
21 -30	243	27.5	85	15.7	328	23.0	152	29.7	65	18.4	217	26.0	71	17.6	40	25.3	111	18.8
31 -40	173	19.6	183	33.8	356	25.0	149	29.2	97	27.4	246	29.5	73	18.1	37	23.4	110	18.6
41 -50	124	14.0	75	13.8	199	14.0	85	16.6	38	10.7	123	14.7	47	11.7	29	18.5	76	12.8
51-60	85	9.6	71	13.1	156	10.9	43	8.4	15	4.2	58	7.0	59	14.6	39	24.7	98	16.6
> 60	69	7.8	33	6.1	102	7.2	17	3.3	9	2.5	26	3.1	41	10.1	35	22.2	76	12.8
Total	884	62.0	542	38.0	1426	100	511	57.8	354	65.3	834	58.5	403	45.6	158	29.2	592	41.5

Legend
M: Males; F: Females; T: Total

3.2 Frequencies of Species of Uropathogens

A total of 403 bacterial uropathogens made up of 11 species were obtained from the patients within the sample period; gram negative bacteria constitute 73.9% of the isolates while gram positive bacteria were 26.1%. *Escherichia coli* was dominant isolate with 347 strains (54.7%), followed by *Staphylococcus aureus* 65 (10.3%), *Enterococcus faecalis* 60 (9.5%), *Proteus mirabilis* 49 (7.7%), *Staphylococcus saprophyticus* 36 (5.7%), *Streptococcus pneumoniae* 25 (3.9%), *Klebsiella pneumoniae* 17 (3.0%), *Pseudomonas aeruginosa* 17 (2.7%), *Enterobacter cloacae* 7 (1.1%), *Acinetobacter baumannii* 7 (0.9%) and *Serratia marcescens* 3 (0.5%). The number of strains obtained from female subjects was 403 (63.6%), while the males contributed 321 strains (36.4%).

Table 2. Frequencies of the species of uropathogens associated with Community acquired UTI

Isolates	Females		Males		Total	
	Frequency	Percent	Frequency	Percent	Frequency	Percent
Escherichia coli	235	58.3	112	48.5	347	54.7
Staphylococcus aureus	39	9.7	26	11.3	65	10.3
Enterococcus faecalis	33	8.2	27	11.7	60	9.5
Proteus mirabilis	32	7.9	17	7.4	49	7.7
Staphylococcus saprophyticus	20	5.0	16	6.9	36	5.7
Streptococcus pneumonia	13	3.2	12	5.2	25	3.9
Klebsiella pneumonia	11	2.7	8	3.5	19	3.0
Pseudomonas aeruginosa	7	1.7	10	4.3	17	2.7
Enterobacter cloacae	7	1.7	0	0	7	1.1
Acinetobacter baumannii	4	1.0	2	0.9	6	0.9
Serratia marcescens	2	0.5	1	0.4	3	0.5
Total	403	63.57	231	36.43	634	100



Fig. 1. Prevalence of gram-positive and gram-positive uropathogens

Table 3. Antimicrobial resistance in uropathogens associated with Community acquired UTI

Isolates	n	nx10	AC	CTX	CEP	CPX	SXT	CN	NIT	OFX	PFX	STR	CR	CR %
Escherichia coli	347	3470	218	119	279	82	239	86	301	113	150	75	1662	48.0
Staphyloccus spp	101	1010	68	40	86	34	83	33	90	50	58	21	563	55.7
Enterococcus faecalis	60	600	34	18	39	13	50	14	49	20	31	11	279	46.5
Proteus mirabils	49	490	31	26	41	12	41	10	40	23	16	12	252	51.4
Streptococcus pneumonia	25	250	15	14	21	6	19	9	23	12	14	3	136	55.2
Klebsiella pneumonia	19	190	16	9	20	4	19	12	19	7	10	5	121	63.7
Pseudomonas aeruginosa	17	170	15	7	15	7	14	7	17	11	10	6	109	64.1
Enterobacter cloacae	7	70	4	3	4	1	5	2	5	3	3	3	33	47.1
Acinetobacter baumannii	6	60	4	2	3	2	4	2	6	3	3	2	31	51.7
Serratia marcescens	3	30	2	1	2	0	2	1	2	1	0	2	13	43.3
Total Percent	634	6340 (100)	407 (64.2)	239 (37.7)	510 (80.4)	161 (25.4)	476 (75.1)	176 (27.8)	552 (87.1)	243 (34.3)	295 (46.5)	140 (22.1)	3199 (50.5)	(50.5)

AC: Amoxicillin/clavulanate; CTX: Ceftriaxone; CEP: Cephalexin; CPX: Ciprofloxacin; SXT: Cotrimoxazole; CN: Gentamicin; NIT: Nitrofurantoin; OFX:Ofloxacin; PFX: Pefloxaacin STR: Streptomycin; n:Nunber of isolates; CR: Cumulative resistance

3.3 Antimicrobial Resistance among the Uropathogens

Over half of the uropathogens reviewed in this were resistant to more than 50% of the tested antimicrobial agents, giving a cumulative resistance of 50.5%. The most resistant uropathogen in this study was *Pseudomonas aeruginosa* with a resistant profile of 64.1%, followed by *Klebsiella pneumoniae* with a profile of 63.7%, *Staphylococci (*55.7%), *Streptococcus pneumoniae* (55.2%), *Acinetobacter baumannii* (51.7%), *Proteus mirabilis* (51.4%), *Escherichia coli* (48.0%), *Enterobacter cloacae* (47.1%), *Enterococcus faecalis* (46.5%) and *Serratia marcescens* (43.3%).

The least effective antimicrobial agent as observed in this study was nitrofurantoin which proved to be ineffective against 87.1% of the uropathogens. This was followed by the cephalosporin cephalexin (80.4%), the folate pathway inhibitor, Cotrimoxazole (75.1%), the penicillin Amoxicillin/clavulanate (64.2%), the fluoroquinolone Pefloxacin (46.5%), the cephalosporin Ceftriaxone (37.7%), the fluoroquinolone Ofloxacin (34.3%), the aminoglycoside gentamicin (27.8%), the fluoroquinolone ciprofloxacin (25.4%) and the aminoglycoside streptomycin (22/1%).

4. DISCUSSION

To an appreciable extent, this study has contributed to ascertaining the prevalence of the bacterial uropathogens and the antimicrobial resistance patterns of the dominant strains associated with community acquired UTI in Port Harcourt, Nigeria. It has also presented empirical evidence for personnel involved in prescription and administration of antibiotics to make more informed decisions in the selection and administration of antimicrobial agents. Out of the 1426 urine samples reviewed in this study, a prevalence of 592 (41.5%) was recorded as yielding bacterial growths. This result aligned very closely with the outcomes of a related study, which reported a UTI prevalence of 40% in Awka, Nigeria [13] and 42.8% reported in Bangladesh [7]; but higher than 24.1% in Gondar, Ethiopia [2], 36.1% in Pakistan [8], 27.4%, in Tanzania [6] 32.1% in Ethiopia [1]. The prevalence is however less than the 64% reported by studies in Uganda [14] and Karaikudi, India [15]. The observed differences may be attributable to local peculiarities like status of antibiotic use and abuse, climatic factors and also the sample sizes. There were more females than males presenting for UTI investigations as well as contributing to the number of uropathogenic isolates with 374 (63.2%) from females while males accounted for 218 (36.8%); this is hardly surprising as females have been known to shoulder a larger chunk of the UTI burden as similar results were obtained elsewhere[9]. Age wise, the highest number of isolates (111; 18.8%) obtained from the 21 to 30 years age bracket, and 110 (18.6%) from the 31 to 40 years bracket could be explained by the fact of being more incidental with most active reproductive ages.

Gram negative uropathogens constitute a majority of the isolates with 298 (73.9%) while the Gram-positive isolates were 105 (26.1%), this is not unexpected given that gram negative bacteria, especially rods have been widely reported as dominant causes of UTI [16,17].

The most prevalent uropathogen in this study is *Escherichia coli*, which has been extensively reported as the commonest etiologic agent, in addition to the other isolates found as regular isolates in UTI related cases [2,4,6]. It is noteworthy that the isolates include members of the ESKAPE pathogens (*Enterococcus* sp., *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Enterobacter* spp.) causing much concerns over high rates of mortality, morbidity and economic losses across the world due to difficulties in treatment arising from their high prevalence of multidrug resistance [11,12,18]. The overall antimicrobial resistance profile is indicative of high resistance rates among the uropathogens, which is a cause for concern. More than half of the isolates were resistant to more than 50% of the antimicrobial agents; while 40% of the antimicrobial agents have AMR profiles above 60%; these are clear indicators that the pathogens are getting increasingly resistant, while the antibiotics are becoming increasingly less effective in the battle against infections [19].

Among the seven classes of antimicrobials tested, the fluoroquinolones, ciprofloxacin, levofloxacin, ofloxacin and pefloxacin; only the aminoglycosides gentamicin and streptomycin and the third-generation Ceftriaxone exhibited some appreciable potentials against the test organisms. This is consistent with a number of previous studies in Nigeria and elsewhere pointing to widespread use and misuse of such widely used antimicrobials like the penicillin (amoxicillin/clavulanate), second generation cephalosporins (cephalexin), cotrimoxazole and nitrofurantoin, though there are conflicting results in few cases [18,20,21].

As a retrospective study, this research relied on previously generated records and so was subject to such limitations as having to adapt the obtained data to fit into the objectives of the study, such as the choice of antibiotics and absence of molecular identification. There is also the limitation of inadequacy of socio-demographics data because the tests were conducted for different objectives. As a cross sectional study, there was no determination of the effects of time and other variables.

5. CONCLUSION

The limitations notwithstanding this study has been able to isolate, identify, ascertain the prevalence and antimicrobial resistance patterns of bacterial uropathogens in Port Harcourt. This outcome of this study will be in the empirical choice of antibiotics in the treatment of UTI especially in third world. The prevalence of AMR makes it necessary to conduct urine cultures and susceptibility testing to identify particular uropathogens and the appropriate antimicrobials in other to curtail increase in AMR among uropathogens. It is suggested that multicenter cohort studies incorporating more antibiotics and be conducted to overcome some of the identified limitations.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscript.

CONSENT AND ETHICAL APPROVAL

The study does not involve any physical contact with persons or clinical specimens; however written consent of the management of the healthcare facility was sought for and obtained before commencement of the study. The research was conducted according to the principles of the Declaration of Helsinki.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Addis T, Mekonnen Y, Ayenew Z, Fentaw S, Biazin H. Bacterial uropathogens and burden of antimicrobial resistance pattern in urine specimens referred to Ethiopian Public Health Institute. PLoS One. 2021;16(11):e0259602.
2. Kasew D, Desalegn B, Aynalem M, Tila S, Diriba D, Afework B, Getie M, Biset S, Baynes HW. Antimicrobial resistance trend of bacterial uropathogens at the university of Gondar comprehensive specialized hospital, northwest Ethiopia: A 10 years retrospective study. PLoS One. 2022;17(4):e0266878.
3. Prasada Rao CMM, Vennila T, Kosanam S, Ponsudha P, Suriyakrishnaan K, Alarfaj AA, Hirad AH, Sundaram SR, Surendhar PA, Selvam N. Assessment of bacterial isolates from the urine specimens of urinary tract infected patient. Biomed Res Int. 2022;2022:4088187.
4. Teferi S, Sahlemariam Z, Mekonnen M, Tamrat R, Bekana T, Adisu Y, Darge T. Uropathogenic bacterial profile and antibiotic susceptibility pattern of isolates among gynecological cases admitted to Jimma Medical Center, South West Ethiopia. Sci Rep. 2023;13(1):7078
5. Petca RC, Negoiță S, Mareș C, Petca A, Popescu RI, Chibelean CB. Heterogeneity of Antibiotics Multidrug-Resistance Profile of Uropathogens in Romanian Population. Antibiotics (Basel). 2021;10(5):523.
6. Silago V, Moremi N, Mtebe M, Komba E, Masoud S, Mgaya FX, Mirambo MM, Nyawale HA, Mshana SE, Matee MI. Multidrug-Resistant uropathogens causing community acquired urinary tract infections among patients attending health facilities in mwanza and dar es Salaam, Tanzania. Antibiotics (Basel). 2022;11(12):1718.
7. Muhammad A, Khan SN, Ali N, Rehman MU, Ali I. Prevalence and antibiotic susceptibility pattern of uropathogens in outpatients at a tertiary care hospital. New Microbes New Infect. 2020;36:100716.
8. Dasgupta C, Rafi MA, Salam MA. High prevalence of multidrug resistant uropathogens: A recent audit of antimicrobial susceptibility testing from a tertiary care hospital in Bangladesh. Pak J Med Sci. 2020;36(6):1297-1302.
9. Ait-Mimoune N, Hassaine H, Boulanoir M. Bacteriological profile of urinary tract infections and antibiotic susceptibility

of *Escherichia coli* in Algeria. Iran J Microbiol. 2022;14(2):156-160.

10. Íñigo M, Coello A, Fernández-Rivas G, Rivaya B, Hidalgo J, Quesada MD, Ausina V. Direct identification of urinary tract pathogens from urine samples, combining urine screening methods and matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2016;54(4):988-93
11. Ndukwu CLC. Microbial communities and antimicrobial resistance patterns in aerobic bacteria associated with the vaginal microbiota: A retrospective study in port harcourt, Nigeria. Asian Journal of Research in Infectious Diseases. 2024; 15(1):39–48. Available:https://doi.org/10.9734/ajrid/2024/v15i1324
12. Ndukwu CLC, Akani NP. Multidrug resistance in klebsiella species isolated from liquid herbal remedies in Port Harcourt, Nigeria International Journal of Pathogen Research. 2023;12(6):83–91. Available:https://doi.org/10.9734/ijpr/2023/v12i6256
13. Ekwealor PA, Ugwu MC, Ezeobi I, Amalukwe G, Ugwu BC, Okezie U. Antimicrobial evaluation of bacterial isolates from urine specimen of patients with complaints of urinary tract infections in Awka, Nigeria. Int J Microbiol. 2016;2016.
14. Carrasco Calzada F, Aguilera-Correa JJ, Cuadros González J, Esteban Moreno J, Roca Biosca D, Pérez-Tanoira R. Urinary tract infection and antimicrobial susceptibility of bacterial isolates in Saint Joseph Kitgum Hospital, Kitgum, Uganda. Antibiotics (Basel). 2022;11(4):504.
15. Thangavelu S, Dhandapani R, Arulprakasam A, Paramasivam R, Chinnathambi A, Ali Alharbi S, Durairaj K, Shrestha A. Isolation, Identification, characterization, and plasmid profile of urinary tract infectious *Escherichia coli* from Clinical Samples. Evid Based Complement Alternat Med. 2022; 2022:7234586.
16. Khatoon I, Khanam S, Azam A, Qadeer S, Naz S, Hassan NU. Incidence pattern, antibiotic susceptibility pattern and associated risk factors of bacterial uropathogens among general population of Pakistan. Infect Drug Resist. 2023; 16:4995-5005.
17. Mekonnen S, Tesfa T, Shume T, Tebeje F, Urgesa K, Weldegebreal F. Bacterial profile, their antibiotic susceptibility pattern, and associated factors of urinary tract infections in children at Hiwot Fana Specialized University Hospital, Eastern Ethiopia. PLoS One. 2023;18(4): e0283637.
18. Idris FN, Nadzir MM. Multi-drug resistant ESKAPE pathogens and the uses of plants as their antimicrobial agents. Arch Microbiol. 2023;205(4):115
19. Mofolorunsho KC, Ocheni HO, Aminu RF, Omatola CA, Olowonibi OO. Prevalence and antimicrobial susceptibility of extended-spectrum beta lactamases-producing *Escherichia coli* and *Klebsiella pneumoniae* isolated in selected hospitals of Anyigba, Nigeria. Afr Health Sci. 2021;21(2):505-512.
20. Diriba K, Awulachew E, Bizuneh B. Identification of bacterial uropathogen and antimicrobial resistance patterns among patients with diabetic and hypertension attending Dilla University General Hospital, Dilla, Ethiopia. Infect Drug Resist. 2023;16:4621-4633.
21. Onanuga A, Selekere TL. Virulence and antimicrobial resistance of common urinary bacteria from asymptomatic students of Niger Delta University, Amassoma, Bayelsa State, Nigeria. J Pharm Bioallied Sci. 2016;8(1):29-3.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/123334